CCT251545 |
CCT251545
ATP competitive inhibitor of CDK19, CDK8
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| CDK19 |
|
|
| CDK8 |
|
|
ATP competitive
35-350 nM
Selectivity
In Vitro Selectivity Assessment
Potency: IC 50 - GSK3alpha: 462 nM, GSK3beta: 690 nM, PRKCQ: 122 nM
Potency Assay Off-Target:
Millipore panel (activity assay), CEREP
Selectivity Assessment Description:
The probe was tested at 1 uM across 293 kinases; the probe inhibited 6 out of the 293 kinases tested ...
Potency Cellular
In Vitro
CDK19
Mode of Action: ATP competitive
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/nchembio.1952
CDK8
Mode of Action: ATP competitive
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/nchembio.1952
In Vivo Validations
Mouse, Rat
Dose: 0.2 mg/kg (IV), 0.5 mg/kg (PO)
Route of delivery:
Intravenous, Oral
Plasma half life:
0.55 h M, 0.97 h R
Systemic clearance:
31 (M), 26 (R) mL/min/kg
Organ of interest (O):
SW620 human colon cancer xenograft
Target engagement assay:
NCr athymic mice bearing established SW620 xenografts were treated with CCT251545 at 70 mg/kg bid for days 0-7 and 10-14. Target engagement was demonstrated by clear reduction of phospho-STAT1(SER727) level at 2 and 6 h after the last dose.
Reference: --
Negative Control Compounds
Compound 7 and 9 (Nat. Chem. Biol. 2015, 11, 973-980)
Chemical Information
| Molecular Formula | C23H24ClN5O |
| SMILEs | Cn1cc(-c2ccc(-c3cncc(Cl)c3N3CCC4(CCNC4=O)CC3)cc2)cn1 |
| InChI | InChI=1S/C23H24ClN5O/c1-28-15-18(12-27-28)16-2-4-17(5-3-16)19-13-25-14-20(24)21(19)29-10-7-23(8-11-29)6-9-26-22(23)30/h2-5,12-15H,6-11H2,1H3,(H,26,30) |
| Molecular weight | 421.17 Da |
| AlogP | 0.0 |
| HBond acceptors | 6 |
| HBond donors | 1 |
| Atoms | 54 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.